Skip to main content
. 2020 Sep 29;2020(9):CD006680. doi: 10.1002/14651858.CD006680.pub3

NCT03206762.

Study name JET‐RANGER Trial ‐ JETStream atherectomy with adjunctive paclitaxel‐coated balloon angioplasty versus plain old balloon angioplasty followed by paclitaxel‐coated balloon
Methods Prospective, single blind (participant), randomised, parallel assignment, multi‐centre study
Participants Estimated enrolment: 255 participants
Ages eligible for study: 18 years and older
Sexes eligible for study: all
General inclusion criteria:
has a Rutherford Clinical Category of 2 to 4; is willing and capable of complying with all follow‐up evaluations at the specified times (including an angiogram at the 1‐year follow‐up visit); is able and willing to provide written informed consent prior to study specific procedures
Angiographic inclusion criteria:
Participant must meet all of the following angiographic inclusion criteria. Unless otherwise specified, the Investigator performing the procedure bases all angiographic inclusion criteria on visual determination at the time of the procedure:

  1. has evidence at the target lesion of ≥ 70% de novo stenosis of (a) ≥ 10 cm length, or (b) any chronic total occlusion (> 1 month by history or known by conventional or CT angiography or arterial duplex ultrasound) in the SFA (at least 1 cm from the bifurcation of the profunda) or popliteal artery, or (c) at least grade 2 or higher calcification as defined by the peripheral arterial calcium scoring system (PACCS) 26;

  2. has evidence of at least one runoff vessel to the ankle/foot of the limb to be treated that does not have significant (< 70%) stenosis during the index procedure;

  3. has a reference vessel diameter of 4 to 7 mm;

  4. has a target lesion an exchangeable guidewire can cross via the true lumen (without using a re‐entry device or a subintimal approach)


General exclusion criteria:

  1. has one or more of the contraindications listed in the JetStream or Ranger IFUs;

  2. has a contraindication or known untreated allergy to antiplatelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used (that cannot be reasonably substituted);

  3. is expected to require cilostazol (Pletal) during the one‐year follow‐up period;

  4. has a hypersensitivity to contrast material that cannot be adequately pretreated;

  5. has known hypersensitivity to treatment device materials including paclitaxel or nitinol;

  6. has known uncontrollable hypercoagulable condition, or refuses blood transfusion;

  7. has life expectancy of less than 24 months;

  8. is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing;

  9. has surgical or endovascular procedure of the target vessel within 30 days prior to the index procedure;

  10. has any planned surgical intervention (requiring hospitalisation) or endovascular procedure within 30 days after the index procedure;

  11. is currently participating in an investigational drug or another device study that may clinically interfere with the study outcomes;

  12. has any comorbid condition that in the judgment of the physician precludes safe percutaneous intervention;

  13. has had a previous peripheral bypass affecting the target vessel (allowable for physician to pass through bypass graft in aorta‐iliac region to get to the target lesion);

  14. has chronic renal insufficiency (eGFR < 30 ml/min or creatinine ≥ 2.5 including dialysis patients);

  15. has planned laser, cryo, TurboHawk or any other treatment except study treatment within 30 days after the index procedure;

  16. has had superficial thrombophlebitis or deep venous thrombus within 30 days prior to index procedure;

  17. has had a stroke within 3 months prior to index procedure;

  18. has had a myocardial infarction within 1 month prior to index hospitalisation;

  19. has history of significant gastrointestinal bleeding in the past 2 months prior to index procedure, or any history of hemorrhagic diathesis;

  20. has a known or suspected systemic infection at the time of the index procedure;

  21. participants with ipsilateral Iliac and CFA disease are allowed in the study but these lesions have to be treated successfully first (< 30% residual) before participant can be enrolled; treatment as per investigator's preference;

  22. aneurysm located in the target vessel or aneurysmal vessel


Angiographic exclusion criteria:
the Investigator performing the procedure bases all angiographic exclusion criteria on visual determination at the time of the procedure;

  1. has < 70% stenosis prior to treatment of the target lesion;

  2. has in‐stent restenosis of the target lesion;

  3. has an acute intraluminal thrombus within the target lesion;

  4. has an aneurysmal target vessel;

  5. participant has already been enrolled in the study or any other study that by the investigator judgment may interfere with the outcome of this trial;

  6. has two or more lesions that require treatment in the target vessel; lesions have to be separated by > 5 cm in order to be considered different lesions; only one lesion per target vessel can be enrolled during the index procedure;

  7. has disease that precludes safe advancement of the Jetstream device to the target lesion;

  8. P3 segments of the popliteal vessel.
Interventions Arm 1: Jetstream atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT D
Arm 2: POBA and then DCB treatment (Ranger or IN.PACT)
Outcomes Primary outcome measures:

  1. TLR at 1 year: TLR is defined as re‐treatment of the index lesion (extended 1 cm proximal and distal to the lesion) at 1 year. For the primary endpoint, intraprocedural bail out stenting of the index lesion is considered meeting a TLR endpoint. (ITT analysis)

  2. MAE at 30 day: unplanned amputation, total mortality or TLR at 30 days (TLR includes bail‐out stenting)
Starting date 28 March 2018
Contact information Midwest Cardiovascular Research Foundation
Notes